These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
240 related articles for article (PubMed ID: 30545222)
1. Infiltration of Prostate Cancer by CD204+ and CD3+ Cells Correlates with ERG Expression and TMPRSS2-ERG Gene Fusion. Burdova A; Rulisek P; Bouchal J; Král M; Student V; Kolar Z Klin Onkol; 2018; 31(6):421-428. PubMed ID: 30545222 [TBL] [Abstract][Full Text] [Related]
2. TMPRSS2-ERG Fusion Promotes Recruitment of Regulatory T cells and Tumor Growth in Prostate Cancer. Shan L; Ji T; Su X; Shao Q; Du T; Zhang S Am J Med Sci; 2018 Jul; 356(1):72-78. PubMed ID: 30049331 [TBL] [Abstract][Full Text] [Related]
3. [TMPRSS2-ERG gene fusion in metastatic prostate cancers: a study of fine needle aspiration specimens]. Xiao L; Zhu XZ; Wang Y; Gong Y; Guo CC Zhonghua Bing Li Xue Za Zhi; 2011 Jun; 40(6):392-6. PubMed ID: 21914348 [TBL] [Abstract][Full Text] [Related]
4. Correlation of ERG immunohistochemistry with molecular detection of TMPRSS2-ERG gene fusion. Sung JY; Jeon HG; Jeong BC; Seo SI; Jeon SS; Lee HM; Choi HY; Kang SY; Choi YL; Kwon GY J Clin Pathol; 2016 Jul; 69(7):586-92. PubMed ID: 26670747 [TBL] [Abstract][Full Text] [Related]
5. Characterizing the molecular features of ERG-positive tumors in primary and castration resistant prostate cancer. Roudier MP; Winters BR; Coleman I; Lam HM; Zhang X; Coleman R; Chéry L; True LD; Higano CS; Montgomery B; Lange PH; Snyder LA; Srivastava S; Corey E; Vessella RL; Nelson PS; Üren A; Morrissey C Prostate; 2016 Jun; 76(9):810-22. PubMed ID: 26990456 [TBL] [Abstract][Full Text] [Related]
6. TMPRSS2:ERG fusion gene occurs less frequently in Chinese patients with prostate cancer. Jiang H; Mao X; Huang X; Zhao J; Wang L; Xu J; Zhang H; Lu Y; Yu Y Tumour Biol; 2016 Sep; 37(9):12397-12402. PubMed ID: 27320318 [TBL] [Abstract][Full Text] [Related]
7. Clinical implications of TMPRSS2-ERG gene fusion expression in patients with prostate cancer treated with radical prostatectomy. Rubio-Briones J; Fernández-Serra A; Calatrava A; García-Casado Z; Rubio L; Bonillo MA; Iborra I; Solsona E; López-Guerrero JA J Urol; 2010 May; 183(5):2054-61. PubMed ID: 20303538 [TBL] [Abstract][Full Text] [Related]
8. Relation of ETS transcription factor family member ERG, androgen receptor and topoisomerase 2β expression to TMPRSS2-ERG fusion status in prostate cancer. Kolar Z; Burdova A; Jamaspishvili T; Bouchal J; Kucerova R; Bienova M; Kral M; Student V Neoplasma; 2014; 61(1):9-16. PubMed ID: 24195515 [TBL] [Abstract][Full Text] [Related]
9. Frequent TMPRSS2-ERG rearrangement in prostatic small cell carcinoma detected by fluorescence in situ hybridization: the superiority of fluorescence in situ hybridization over ERG immunohistochemistry. Schelling LA; Williamson SR; Zhang S; Yao JL; Wang M; Huang J; Montironi R; Lopez-Beltran A; Emerson RE; Idrees MT; Osunkoya AO; Man YG; Maclennan GT; Baldridge LA; Compérat E; Cheng L Hum Pathol; 2013 Oct; 44(10):2227-33. PubMed ID: 23850495 [TBL] [Abstract][Full Text] [Related]
10. Expression of steroid and peptide hormone receptors, metabolic enzymes and EMT-related genes in prostate tumors in relation to the presence of the TMPRSS2/ERG fusion. Gerashchenko GV; Mevs LV; Chashchina LI; Pikul MV; Gryzodub OP; Stakhovsky EO; Kashuba VI Exp Oncol; 2018 Jun; 40(2):101-108. PubMed ID: 29949537 [TBL] [Abstract][Full Text] [Related]
11. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer. Hermans KG; van Marion R; van Dekken H; Jenster G; van Weerden WM; Trapman J Cancer Res; 2006 Nov; 66(22):10658-63. PubMed ID: 17108102 [TBL] [Abstract][Full Text] [Related]
12. Altered PCA3 and TMPRSS2-ERG expression in histologically benign regions of cancerous prostates: a systematic, quantitative mRNA analysis in five prostates. Väänänen RM; Ochoa NT; Boström PJ; Taimen P; Pettersson K BMC Urol; 2015 Aug; 15():88. PubMed ID: 26294063 [TBL] [Abstract][Full Text] [Related]
13. TMPRSS2:ERG gene aberrations may provide insight into pT stage in prostate cancer. Krstanoski Z; Vokac NK; Zagorac A; Pospihalj B; Munda M; Dzeroski S; Golouh R BMC Urol; 2016 Jul; 16(1):35. PubMed ID: 27377958 [TBL] [Abstract][Full Text] [Related]
14. Genetic interaction between Tmprss2-ERG gene fusion and Nkx3.1-loss does not enhance prostate tumorigenesis in mouse models. Linn DE; Bronson RT; Li Z PLoS One; 2015; 10(3):e0120628. PubMed ID: 25780911 [TBL] [Abstract][Full Text] [Related]
15. Morphological features of TMPRSS2-ERG gene fusion prostate cancer. Mosquera JM; Perner S; Demichelis F; Kim R; Hofer MD; Mertz KD; Paris PL; Simko J; Collins C; Bismar TA; Chinnaiyan AM; Rubin MA J Pathol; 2007 May; 212(1):91-101. PubMed ID: 17385188 [TBL] [Abstract][Full Text] [Related]
16. Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer. FitzGerald LM; Agalliu I; Johnson K; Miller MA; Kwon EM; Hurtado-Coll A; Fazli L; Rajput AB; Gleave ME; Cox ME; Ostrander EA; Stanford JL; Huntsman DG BMC Cancer; 2008 Aug; 8():230. PubMed ID: 18694509 [TBL] [Abstract][Full Text] [Related]
17. TMPRSS2:ETS fusions and clinicopathologic characteristics of prostate cancer patients from Eastern China. Dong J; Xiao L; Sheng L; Xu J; Sun ZQ Asian Pac J Cancer Prev; 2014; 15(7):3099-103. PubMed ID: 24815454 [TBL] [Abstract][Full Text] [Related]
18. Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer. Furusato B; Gao CL; Ravindranath L; Chen Y; Cullen J; McLeod DG; Dobi A; Srivastava S; Petrovics G; Sesterhenn IA Mod Pathol; 2008 Feb; 21(2):67-75. PubMed ID: 18065961 [TBL] [Abstract][Full Text] [Related]
19. Retention of Interstitial Genes between Murphy SJ; Kosari F; Karnes RJ; Nasir A; Johnson SH; Gaitatzes AG; Smadbeck JB; Rangel LJ; Vasmatzis G; Cheville JC Cancer Res; 2017 Nov; 77(22):6157-6167. PubMed ID: 29127096 [No Abstract] [Full Text] [Related]
20. ERG rearrangement is present in a subset of transition zone prostatic tumors. Falzarano SM; Navas M; Simmerman K; Klein EA; Rubin MA; Zhou M; Magi-Galluzzi C Mod Pathol; 2010 Nov; 23(11):1499-506. PubMed ID: 20693982 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]